Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients.

Garassino MC, Gelibter AJ, Grossi F, Chiari R, Parra HS, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini EE, Quadrini S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F.

J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30553-7. doi: 10.1016/j.jtho.2018.04.025. [Epub ahead of print]

PMID:
29730379
2.

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.

Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.

Cancer Immunol Res. 2018 Apr 26. doi: 10.1158/2326-6066.CIR-17-0594. [Epub ahead of print]

PMID:
29700053
3.

PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?

Raimondi C, Carpino G, Nicolazzo C, Gradilone A, Gianni W, Gelibter A, Gaudio E, Cortesi E, Gazzaniga P.

Oncoimmunology. 2017 Apr 20;6(12):e1315488. doi: 10.1080/2162402X.2017.1315488. eCollection 2017.

4.

Burned-Out Testicular Cancer: Really a Different History?

Mosillo C, Scagnoli S, Pomati G, Caponnetto S, Mancini ML, Bezzi M, Cortesi E, Gelibter A.

Case Rep Oncol. 2017 Sep 20;10(3):846-850. doi: 10.1159/000480493. eCollection 2017 Sep-Dec.

5.

Use of Adjuvant Chemotherapy After Surgery in Patients With Colon Cancer.

Gelibter AJ, Mosillo C, Sirgiovanni G.

JAMA Surg. 2017 Sep 1;152(9):895. doi: 10.1001/jamasurg.2017.1617. No abstract available.

PMID:
28614583
6.

Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab.

Caponnetto S, Iannantuono GM, Barchiesi G, Magri V, Gelibter A, Cortesi E.

Oncology. 2017;93(1):62-66. doi: 10.1159/000464328. Epub 2017 Apr 14.

PMID:
28407622
7.

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.

Vari S, Pilotto S, Maugeri-Saccà M, Ciuffreda L, Cesta Incani U, Falcone I, Del Curatolo A, Ceribelli A, Gelibter A, De Maria R, Tortora G, Cognetti F, Bria E, Milella M.

Expert Opin Drug Discov. 2013 Nov;8(11):1381-97. doi: 10.1517/17460441.2013.843523. Epub 2013 Oct 3. Review.

PMID:
24088065
8.

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M.

World J Gastroenterol. 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511.

9.

Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

Grande R, Gemma D, Sperduti I, Gelibter A, Giampaolo MA, Trombetta G, Nelli F, Gamucci T.

Springerplus. 2013 Apr 25;2(1):185. doi: 10.1186/2193-1801-2-185. Print 2013 Dec.

10.

Molecular and genetic bases of pancreatic cancer.

Vaccaro V, Gelibter A, Bria E, Iapicca P, Cappello P, Di Modugno F, Pino MS, Nuzzo C, Cognetti F, Novelli F, Nistico P, Milella M.

Curr Drug Targets. 2012 Jun;13(6):731-43. Review.

11.

EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.

Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, Antoniani B, Merola R, Gelibter A, Cuppone F, D'Alicandro V, Ceribelli A, Rinaldi M, Cianciulli A, Felicioni L, Malatesta S, Marchetti A, Mottolese M, Cognetti F.

J Thorac Oncol. 2012 Apr;7(4):672-80. doi: 10.1097/JTO.0b013e31824a8bde.

12.

Emerging pathways and future targets for the molecular therapy of pancreatic cancer.

Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M.

Expert Opin Ther Targets. 2011 Oct;15(10):1183-96. doi: 10.1517/14728222.2011.607438. Epub 2011 Aug 7. Review.

PMID:
21819318
13.

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, Sperduti I, Gelibter A, Scagliotti GV, Cognetti F, Giannarelli D.

Ann Oncol. 2011 Oct;22(10):2277-85. doi: 10.1093/annonc/mdq742. Epub 2011 Feb 16. Review.

14.

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.

Milella M, Gelibter AJ, Pino MS, Bossone G, Marolla P, Sperduti I, Cognetti F.

Oncologist. 2010;15(2):e1-4. doi: 10.1634/theoncologist.2008-0135.

15.

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A, Iacobelli S, Cognetti F, Buttitta F.

Neoplasia. 2009 Oct;11(10):1084-92.

16.

Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.

Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, Bria E, Carpanese L, Ruggeri EM, Carlini P, Cognetti F.

Oncology. 2009;76(4):254-61. doi: 10.1159/000205388. Epub 2009 Feb 26.

PMID:
19246950
17.

COX-2 targeting in cancer: a new beginning?

Milella M, Metro G, Gelibter A, Pino SM, Cognetti F, Fabi A.

Ann Oncol. 2008 Jun;19(6):1209-10. doi: 10.1093/annonc/mdn286. Epub 2008 May 13. No abstract available.

PMID:
18477580
18.

Bevacizumab: one treatment for all the seasons?

Gelibter AJ, Di Segni S, Zeuli M, Cognetti F.

J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2. doi: 10.1200/JCO.2007.15.0292. No abstract available. Erratum in: J Clin Oncol 2008 Apr 10;26(11) 1911.

PMID:
18202430
19.

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.

Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, Sperduti I, Russillo M, Gelibter A, Ferretti G, Tomao S, Milella M, Cognetti F.

Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25. Epub 2007 Dec 6.

PMID:
18071704
20.

A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.

Gelibter AJ, Gamucci T, Pollera CF, Di Costanzo F, Nuzzo C, Gabriele A, Signorelli C, Gasperoni S, Ferraresi V, Giannarelli D, Cognetti F, Zeuli M.

Curr Med Res Opin. 2007 Sep;23(9):2117-23.

PMID:
17651538
21.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma.

Carlini P, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Ruggeri EM, Milella M, Nuzzo C, Cecere FL, Gelibter A, Pino MS, Nisticò C, Cuppone F, Metro G, Terzoli E, Cognetti F, Ferretti G.

Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36. Review.

PMID:
17594187
22.

Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.

Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F, Giannarelli D.

Cancer. 2007 Aug 1;110(3):525-33.

23.

Old age: biologic versus chronologic.

Gelibter AJ, Di Segni S, Zeuli M, Milella M, Ferretti G, Nuzzo C, Cognetti F.

J Clin Oncol. 2007 Feb 20;25(6):e8. No abstract available.

PMID:
17308262
24.

Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.

Ceribelli A, Pino MS, Gelibter AJ, Milella M, Cecere FL, Caterino M, Facciolo F, Mirri A, Cognetti F.

Cancer. 2007 Feb 15;109(4):727-31.

25.

Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?

Gelibter AJ, Lonardi S, Di Segni S, Fontana A, Loupakis F, Cognetti F, Labianca R.

J Clin Oncol. 2006 Oct 1;24(28):4668-9; author reply 4669. No abstract available.

PMID:
17008710
26.

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.

Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Di Cosimo S, Ruggeri EM, Milella M, Ciccarese M, Cecere FL, Gelibter A, Nuzzo C, Cognetti F, Terzoli E, Carlini P.

Br J Cancer. 2006 Jun 19;94(12):1789-96. Epub 2006 May 30.

27.

Non-small cell lung cancer: early stages.

Bria E, Ceribelli A, Trovò MG, Gelibter A, Gigante M, Calabrò E, Cuppone F, Cognetti F, Terzoli E, Pastorino U.

Ann Oncol. 2006 Mar;17 Suppl 2:ii17-21. Review. No abstract available.

PMID:
16608973
28.

Severe rhabdomyolysis associated with pemetrexed-based chemotherapy.

Ceribelli A, Cecere FL, Milella M, Facciolo F, Gelibter A, Cognetti F.

Lancet Oncol. 2006 Apr;7(4):353. No abstract available.

PMID:
16574552
29.

Molecular stool testing for the early detection of colorectal cancer: swan song for p53?

Ferretti G, Felici A, Ciccarese M, Papaldo P, Carlini P, Fabi A, Gelibter A, Cognetti F.

Ann Oncol. 2006 Jun;17(6):1026. Epub 2005 Nov 15. No abstract available.

PMID:
16291578
30.

Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?

Ferretti G, Bria E, Felici A, Carlini P, Giannarelli D, Ciccarese M, Papaldo P, Fabi A, Gelibter A, Cognetti F.

Ann Oncol. 2006 Mar;17(3):528-9. Epub 2005 Oct 26. No abstract available.

PMID:
16251205
31.

Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?

Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandala M, Papaldo P, Nistico C, Fabi A, Cuppone F, Gelibter A, Terzoli E, Cognetti F.

J Clin Oncol. 2005 Oct 1;23(28):7248-50; author reply 7250. No abstract available.

PMID:
16192623
32.

Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer.

Gelibter A, Ceribelli A, Pollera CF, Milella M, Moscetti L, Sperduti I, Cognetti F.

J Cancer Res Clin Oncol. 2005 Dec;131(12):783-8. Epub 2005 Nov 15.

PMID:
16184381
33.

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.

Gelibter A, Malaguti P, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Carboni F, Ettorre GM, Pellicciotta M, Giannarelli D, Terzoli E, Cognetti F, Milella M.

Cancer. 2005 Sep 15;104(6):1237-45.

34.

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.

Felici A, Carlini P, Ruggeri EM, Gamucci T, Pollera CF, De Marco S, Fariello AM, Moscetti L, Gelibter A, Adami E, Sperduti I, Cognetti F.

Cancer Chemother Pharmacol. 2006 Jan;57(1):59-64. Epub 2005 Nov 5.

PMID:
16001173
35.

Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?

Ferretti G, Bria E, Carlini P, Felici A, Giannarelli D, Cuppone F, Papaldo P, Nisticò C, Fabi A, Gelibter A, Terzoli E, Cognetti F.

Gut. 2005 Jun;54(6):891. No abstract available.

36.

PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.

Gelibter A, Milella M, Ceribelli A, Zeuli M, Ferraresi V, Vecchione A, Cognetti F.

Anticancer Res. 2004 Sep-Oct;24(5B):3147-51.

37.

New approaches to prevent intestinal toxicity of irinotecan-based regimens.

Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A, Di Palma M.

Cancer Treat Rev. 2004 Oct;30(6):555-62. Review.

PMID:
15325035
38.

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.

Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Malaguti P, Pellicciotta M, Terzoli E, Cognetti F.

Cancer. 2004 Jul 1;101(1):133-8.

39.

Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.

Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandalà M, Milella M, Ruggeri EM, Cognetti F.

Ann Oncol. 2004 Jul;15(7):1065-71.

PMID:
15205200
40.

Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis.

Hardan I, Rothman R, Gelibter A, Cohen N, Shimoni A, Sokolovsky M, Reichart M, Ishoev G, Amariglio N, Rechavi G, Nagler A, Trakhtenbrot L.

Exp Hematol. 2004 Mar;32(3):254-60.

PMID:
15003310
41.

Docetaxel in advanced gastric cancer--review of the main clinical trials.

Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, Gelibter A, Felici A, Papaldo P, Cognetti F.

Acta Oncol. 2003;42(7):693-700. Review.

PMID:
14690154
42.

Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.

Gelibter A, Ceribelli A, Milella M, Mottolese M, Vocaturo A, Cognetti F.

J Exp Clin Cancer Res. 2003 Sep;22(3):481-5.

PMID:
14582710
43.

Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.

Serrone L, Nardoni C, Gelibter A, Felici A, Cognetti F.

J Exp Clin Cancer Res. 2002 Jun;21(2):181-4.

PMID:
12148575
44.

Malignant bronchial Abrikossoff's tumor and small cell lung cancer: a case report and review.

Lauro S, Trasatti L, Bria E, Gelibter A, Larosa G, Vecchione A.

Anticancer Res. 2001 Jan-Feb;21(1B):563-5.

PMID:
11299804
45.

Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.

Lauro S, Trasatti L, Bordin F, Lanzetta G, Bria E, Gelibter A, Reale MG, Vecchione A.

Anticancer Res. 1999 Jul-Aug;19(4C):3511-5.

PMID:
10629644
46.

Antiblastic chemotherapy in the presence of abdominal aorta aneurysm (AAA): guidelines.

Lauro S, Lanzetta G, Bria E, Trasatti L, Gelibter A, Vecchione A.

Anticancer Res. 1999 Mar-Apr;19(2B):1439-44. Review.

PMID:
10365120

Supplemental Content

Loading ...
Support Center